Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) have been given a consensus recommendation of “Buy” by the fifteen brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $91.45.

A number of research firms recently weighed in on GBT. Goldman Sachs Group reaffirmed a “neutral” rating and set a $75.00 target price on shares of Global Blood Therapeutics in a report on Wednesday, May 29th. BidaskClub lowered shares of Global Blood Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday. Oppenheimer increased their price target on shares of Global Blood Therapeutics from $82.00 to $89.00 and gave the stock an “outperform” rating in a report on Thursday, May 9th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $75.00 price target on shares of Global Blood Therapeutics in a report on Sunday. Finally, Wedbush reissued an “outperform” rating and issued a $103.00 price target on shares of Global Blood Therapeutics in a report on Monday.

Shares of GBT stock traded down $0.68 during trading on Friday, reaching $47.46. 197,237 shares of the company’s stock traded hands, compared to its average volume of 586,890. The company has a market capitalization of $2.86 billion, a P/E ratio of -13.92 and a beta of 1.51. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.79 and a quick ratio of 16.79. The stock has a 50-day moving average price of $54.12. Global Blood Therapeutics has a 1 year low of $30.15 and a 1 year high of $64.94.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.05). During the same quarter in the prior year, the firm posted ($0.78) EPS. Equities research analysts forecast that Global Blood Therapeutics will post -3.87 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Nuveen Asset Management LLC bought a new stake in Global Blood Therapeutics during the 2nd quarter valued at about $11,530,000. Price T Rowe Associates Inc. MD increased its stake in Global Blood Therapeutics by 15.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,176,942 shares of the company’s stock valued at $219,707,000 after purchasing an additional 572,808 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in Global Blood Therapeutics by 29.7% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 49,436 shares of the company’s stock valued at $2,600,000 after purchasing an additional 11,313 shares in the last quarter. Highbridge Capital Management LLC increased its stake in Global Blood Therapeutics by 100.0% during the 2nd quarter. Highbridge Capital Management LLC now owns 80,000 shares of the company’s stock valued at $4,208,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Global Blood Therapeutics during the 2nd quarter valued at about $913,000.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Recommended Story: Trading Ex-Dividend Strategy

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.